发布求助
文献互助 智能选刊 最新文献

Pharmadeals Review最新文献

筛选
英文 中文
IMS PharmaDeals Review of 2014 2014年IMS PharmaDeals回顾
Pharmadeals Review Pub Date : 2015-10-03 DOI: 10.3833/pdr.v2015i3.2096
Taskin Ahmed, Heather Cartwright
{"title":"IMS PharmaDeals Review of 2014","authors":"Taskin Ahmed, Heather Cartwright","doi":"10.3833/pdr.v2015i3.2096","DOIUrl":"https://doi.org/10.3833/pdr.v2015i3.2096","url":null,"abstract":"M&A and partnering deal values soared in 2014, in what was a record-breaking year for dealmaking in the life sciences sector. After mostly abstaining from acquisitions in 2013, big pharma appetite for M&A increased significantly, despite an overall downturn in deal activity, and the multibillion dollar deal returned to prominence. Creativity in M&A also emerged, as evidenced by the asset swapping between GlaxoSmithKline (GSK) and Novartis, and speciality pharma consolidation continued apace. On average, licensing upfront payments and deal values increased markedly as compared to 2013 with large pharmaceutical companies willing to pay a sizeable premium for attractive clinical-stage assets in order to compete in key therapeutic areas. For the second year running, AstraZeneca was the most prolific dealmaker with Johnson & Johnson (J&J) and Roche following closely behind. Oncology, and the field of immuno-oncology in particular, continued to dominate the dealmaking landscape.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90400213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9 Juno Therapeutics和Editas Medicine合作开发使用CRISPR/Cas9的下一代CAR-T疗法
Pharmadeals Review Pub Date : 2015-06-19 DOI: 10.3833/pdr.v2015i6.2108
Keshav Mahawar, Heather Cartwright
{"title":"Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9","authors":"Keshav Mahawar, Heather Cartwright","doi":"10.3833/pdr.v2015i6.2108","DOIUrl":"https://doi.org/10.3833/pdr.v2015i6.2108","url":null,"abstract":"Signalling its intent to stay at the head of the cellular immunotherapy field, Juno Therapeutics has agreed to collaborate with genome editing specialist Editas Medicine to create next-generation chimeric antigen receptor (CAR-T) and high-affinity T cell receptor (TCR) therapies for the treatment of cancer. With the deal, Juno will leverage Editas’ CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) technology with the aim of expanding its pipeline into solid tumours.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87907643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma 阿斯利康通过与Celgene和Innate Pharma的交易加强了免疫肿瘤产品组合
Pharmadeals Review Pub Date : 2015-05-15 DOI: 10.3833/PDR.V2015I5.2102
Smita Mishra, Heather Cartwright
{"title":"AstraZeneca Bolsters Immuno-Oncology Portfolio via Deals with Celgene and Innate Pharma","authors":"Smita Mishra, Heather Cartwright","doi":"10.3833/PDR.V2015I5.2102","DOIUrl":"https://doi.org/10.3833/PDR.V2015I5.2102","url":null,"abstract":"With a pair of deals worth more than US$1.7 B, AstraZeneca has taken steps to strengthen and expand its immuno-oncology portfolio, partnering with Innate Pharma for the co-development and commercialisation of the Phase II anti-NKG2A antibody IPH2201 and out-licensing its immune checkpoint inhibitor MEDI4736 (durvalumab) to Celgene for development in haematological malignancies. AstraZeneca also plans to test the two assets in combination in solid tumours, adding to the company’s broad programme of combination trials in immuno-oncology.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87365462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential 艾伯维(AbbVie)押注210亿美元，认为pharmacyics公司的Imbruvica®将实现上升潜力
Pharmadeals Review Pub Date : 2015-03-21 DOI: 10.3833/PDR.V2015I3.2099
Heather Cartwright
{"title":"AbbVie Gambles US$21 B that Pharmacyclics’ Imbruvica® will Achieve Upside Potential","authors":"Heather Cartwright","doi":"10.3833/PDR.V2015I3.2099","DOIUrl":"https://doi.org/10.3833/PDR.V2015I3.2099","url":null,"abstract":"Paying a huge premium to acquire an on-market asset with multi billion dollar revenue potential, AbbVie has trumped Johnson & Johnson (J&J) with a US$21 B deal to acquire Pharmacyclics. Key to the acquisition is Imbruvica® (ibrutinib), a Bruton’s tyrosine kinase (Btk) inhibitor that is approved for a number of B-cell malignancies.The purchase price has shocked many industry observers, effectively valuing Imbruvica as it does at a staggering US$42 B given J&J’s 50% interest in the drug. After being forced to halt its bid to acquire Shire, the deal is another attempt by AbbVie to diversify its business beyond Humira® (adalimumab).","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84989844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class BMS以8亿美元先期投资Flexus临床前IDO1抑制剂为同类最佳
Pharmadeals Review Pub Date : 2015-03-18 DOI: 10.3833/pdr.v2015i3.2098
Heather Cartwright
{"title":"BMS Bets US$800 M Upfront That Flexus’ Preclinical IDO1 Inhibitor Is Best-in-Class","authors":"Heather Cartwright","doi":"10.3833/pdr.v2015i3.2098","DOIUrl":"https://doi.org/10.3833/pdr.v2015i3.2098","url":null,"abstract":"In by far the largest deal to date in the immuno-oncology sector in terms of upfront consideration, Bristol-Myers Squibb (BMS) has agreed to acquire start-up Flexus Biosciences for US$800 M plus up to US$450 M in development milestones that could be achieved within 3 years. The deal adds a preclinical-stage IDO1 (indoleamine 2,3-dioxygenase 1)inhibitor programme to BMS’ burgeoning cancer immunotherapy pipeline. On the same day, the company also announced a collaboration with Rigel Pharmaceuticals that is focused on another immunotherapeutic approach, namely TGF beta inhibition.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86562205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perrigo to Become Top 5 OTC Player in Europe with US$4.5 B Omega Pharma Acquisition 培瑞高以45亿美元收购欧米茄制药，成为欧洲五大非处方药生产商
Pharmadeals Review Pub Date : 2014-11-22 DOI: 10.3833/PDR.V2014I11.2077
Sayani Datta, Heather Cartwright
{"title":"Perrigo to Become Top 5 OTC Player in Europe with US$4.5 B Omega Pharma Acquisition","authors":"Sayani Datta, Heather Cartwright","doi":"10.3833/PDR.V2014I11.2077","DOIUrl":"https://doi.org/10.3833/PDR.V2014I11.2077","url":null,"abstract":"Continuing the unprecedented wave of consolidation seen in the OTC pharmaceutical sector thus far in 2014, Perrigo has agreed to acquire Belgium-based Omega Pharma for €3.6 B (US$4.5 B), including the assumption of €1.1 B (US$1.4 B) in debt. The deal will accelerate Perrigo’s international growth strategy, diversifying its revenue streams and giving it access to an established commercial infrastructure in Europe.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"112 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85368949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meda Asserts Independence with US$3.1 B Rottapharm Acquisition 美达以31亿美元收购Rottapharm宣告独立
Pharmadeals Review Pub Date : 2014-11-09 DOI: 10.3833/pdr.v2014i9.2060
Heather Cartwright
{"title":"Meda Asserts Independence with US$3.1 B Rottapharm Acquisition","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i9.2060","DOIUrl":"https://doi.org/10.3833/pdr.v2014i9.2060","url":null,"abstract":"Having rejected two takeover bids from Mylan earlier in 2014, Sweden’s Meda has agreed to acquire the Italian speciality pharmaceutical company Rottapharm Madaus for a total consideration of SEK21.2 B (US$3.1 B), including net debt of SEK2.8 B (US$407 M). The deal comes only weeks after family owned Rottapharm withdrew a planned IPO citing unfavourable market conditions. The acquisition, the largest in Meda’s history, will bolster the company’s consumer healthcare business and increase its emerging market revenues by 50%.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"172 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79502720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte BMS通过与CytomX和Incyte的交易继续推进免疫肿瘤学的发展
Pharmadeals Review Pub Date : 2014-11-06 DOI: 10.3833/PDR.V2014I6.2041
Heather Cartwright
{"title":"BMS Continues Immuno-Oncology Push via Deals with CytomX and Incyte","authors":"Heather Cartwright","doi":"10.3833/PDR.V2014I6.2041","DOIUrl":"https://doi.org/10.3833/PDR.V2014I6.2041","url":null,"abstract":"Continuing the high level of deal-making activity seen in the immuno-oncology sector thus far in 2014, Bristol-Myers Squibb (BMS) has formed separate deals with CytomX Therapeutics and Incyte. The deal with CytomX is focused on the discovery, development and commercialisation of masked antibody Probody™ therapies against up to four cancer targets. BMS will also collaborate with Incyte to evaluate its programmed cell death-1 (PD-1) inhibitor nivolumab in combination with Incyte’s INCB24360 in a Phase I/II trial.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89882960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IMS PharmaDeals Half-Year Review of 2015 IMS PharmaDeals 2015年半年回顾
Pharmadeals Review Pub Date : 2014-10-09 DOI: 10.3833/PDR.V2014I9.2059
Heather Cartwright, Taskin Ahmed
{"title":"IMS PharmaDeals Half-Year Review of 2015","authors":"Heather Cartwright, Taskin Ahmed","doi":"10.3833/PDR.V2014I9.2059","DOIUrl":"https://doi.org/10.3833/PDR.V2014I9.2059","url":null,"abstract":"Despite a significant downturn in overall deal activity in the life sciences sector, appetite for M&A remained reasonably high in the first half of 2015. Big pharma involvement was somewhat subdued compared to the same period the previous year, however, and concerns surfaced over the emergence of a biotech bubble as a number of purchasers faced accusations of overpaying. Speciality pharma takeovers comprised a sizeable proportion of the top 10 M&A deals of H1 2015 as ranked by total deal value. Mean licensing upfront payments and deal values decreased markedly as compared to H1 2014, in part owing to the absence of deals with record-breaking upfront payments. AstraZeneca retained its title as the most prolific dealmaker in H1 2015, being party to deals with some of the largest upfront payments of the period, although Johnson & Johnson (J&J) was not far behind thanks to a plethora of early-stage R&D collaborations. Oncology once again dominated the dealmaking landscape, with partnering in immuno-oncology in particular reaching new heights in parallel with the evolution of the field.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"55 162","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91437188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi MannKind终于在赛诺菲找到了吸入胰岛素Afrezza®的合作伙伴
Pharmadeals Review Pub Date : 2014-09-24 DOI: 10.3833/pdr.v2014i9.2062
Heather Cartwright
{"title":"MannKind Finally Finds a Partner for its Inhaled Insulin Afrezza® in Sanofi","authors":"Heather Cartwright","doi":"10.3833/pdr.v2014i9.2062","DOIUrl":"https://doi.org/10.3833/pdr.v2014i9.2062","url":null,"abstract":"Sanofi has licensed global rights to MannKind’s rapid-acting inhaled insulin Afrezza® (insulin human), which was approved by the US FDA in June 2014 for the treatment of diabetes mellitus at the third attempt. The drug will diversify Sanofi’s diabetes portfolio ahead of the 2015 patent expiry of its long-acting basal insulin analogue Lantus® (insulin glargine), which leads the diabetes market with sales of more than US$7 B in 2013. Considerable uncertainty surrounds the commercial potential of Afrezza, however.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2014-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74376033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信